

User's Manual

Human IFN γ ELISA

Sandwich Enzyme-Linked Immunosorbent Assay for the detection
of Human Interferon Gamma (IFN γ)

REF

IB99533



96

Storage: 2-8°C

RUO

For research use only, not for use in diagnostic procedures.

Contents

1. Introduction	3
2. Principles of Method	3
3. Intended Use	4
4. Storage and Stability	4
5. Chemical Hazard	4
6. Kit Contents	5
7. Materials Required But Not Provided	6
8. Reagent preparation	6
1) Human IFN γ standard	6
2) Secondary Antibody	6
3) Streptavidin- HRP	7
4) Washing buffer	7
9. Assay Procedure	8
10. Characteristics	9
1) Typical result	9
2) Sensitivity	10
3) Specificity	11
4) Precision	11
5) Recovery	11
11. Troubleshooting	12
12. Reference	13

1. Introduction

Interferon gamma (IFN γ) is a dimerized soluble cytokine that is the only member of the type II class of interferons. The existence of this interferon, which early in its history was known as immune interferon, was recognized in 1970 when tuberculin-sensitized peritoneal cells were challenged with PPD and resulting supernatants were shown to inhibit growth of vesicular stomatitis virus. That report also contained the basic observation underlying the now widely employed interferon gamma release assay used to test for TB. This interferon was later called macrophage-activating factor, a term now used to describe a larger family of proteins to which IFN γ belongs. In humans, the IFN γ protein is encoded by the *IFNG* gene. IFN γ , or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. IFN γ is an important activator of macrophages. Aberrant IFN γ expression is associated with a number of autoinflammatory and autoimmune diseases. The importance of IFN γ in the immune system stems in part from its ability to inhibit viral replication directly, and most importantly from its immunostimulatory and immunomodulatory effects. IFN γ is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 Th1 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops.

2. Principles of Method

The design of this assay is based on a sandwich Enzyme-Linked Immunosorbent Assay (ELISA). The microtiter plate provided in this kit has been pre-coated with a monoclonal antibody specific to Human IFN γ . Samples are pipetted into these wells. Nonbound Human IFN γ and other components of the sample should be removed by washing, then monoclonal antibody specific to Human IFN γ added. In order to quantitatively determine the amount of Human IFN γ present in the sample, Streptavidin Horseradish Peroxidase (HRP) should be added to each microplate well. The final step, a TMB-substrate solution added to each well. Finally, a sulfuric acid solution is added and the resulting yellow colored product is measured at 450nm. Since the increases in absorbency is directly proportional to the amount of captured Human IFN γ .

3. Intended Use

The IBL-AMERICA Human IFN γ ELISA kit is to be used for the determination of Human IFN γ in Human serum, Human plasma, cell lysate, culture supernatants and buffered solution. The assay will recognize native and recombinant Human IFN γ .

This kit has been configured for research use only and is not to be used in diagnostic procedures.

4. Storage and Stability

All kit components of this kit are stable at 2 to 8°C. Any unused reconstituted standard should be discarded or frozen at -70°C. Standard can be frozen and thawed one time only without loss of immunoreactivity.

5. Chemical Hazard

- Stop solution: This reagent is an irritant to eyes, skin and mucous membranes. Avoid contact with eyes, skin and clothing. Wear suitable protective clothing, gloves and eye protection. In the event of contact with eyes or skin, wash immediately with plenty of water.
- Standard protein and 2nd Antibody containing Sodium Azide as a preservative.

6. Kit Contents

Contents	Number	Volume
96 Well Plate	1 (in aluminum foil bag with desiccant)	
Washing Buffer	2	(20X) 25 ml
Standard Protein	1 Glass vial (lyophilized)	
Standard/Sample Dilution Buffer	1	25 ml
Secondary Antibody	1 Glass vial (lyophilized)	
Streptavidin HRP(X100)	1	150 μ l
Secondary antibody/ Streptavidin HRP Dilution Buffer	1	25 ml
Substrate (TMB)	1	15 ml
Stop Solution	1	15 ml
Protocol booklet	1	
Plate sealers	2	

- ① 96 Well Plate
: Human IFN γ microtiter plate, one plate of 96 wells (8 well strips x 12).
A plate using break-apart strips coated with a mouse monoclonal antibody specific to Human IFN γ .
 - ② Standard Protein
: Recombinant Human IFN γ .
 - ③ Secondary Antibody
: Biotinylated anti Human IFN γ antibody.
 - ④ Streptavidin HRP
: Streptavidin Horseradish Peroxidase (HRP, enzyme)
 - ⑤ Substrate (Stabilized chromogen)
: Tetramethylbenzidine (TMB) solution
 - ⑥ Stop Solution
: 1N solution of sulfuric acid (H₂SO₄).
 - ⑦ Plate sealer
: Adhesive sheet.
- Do not mix or interchange different reagents from various kit lots.

7. Materials Required But Not Provided

- ① Microtiter plate reader capable of measurement at or near 450nm.
- ② Calibrated, adjustable precision pipettes, preferably with disposable plastic tips (A manifold multi-channel pipette is desirable for large assays.)
- ③ Distilled or deionized water
- ④ Data analysis and graphing software
- ⑤ Vortex mixer
- ⑥ Polypropylene tubes for diluting and aliquoting standard
- ⑦ Absorbent paper towels
- ⑧ Calibrated beakers and graduated cylinders of various sizes

8. Reagent Preparation

1) Human IFN γ standard

1. Reconstitute the lyophilized **Human IFN γ** standard by adding 1 ml of *Standard/Sample Dilution Buffer* to make the 4 ng/ml standard stock solution. Allow solution to sit at RT for 5 minutes, then gently vortex to mix completely. Use within one hour of reconstituting.

2. Prepare 1 ml of 1000 pg/ml top standard by adding 250 μ l of the above stock solution in 750 μ l of *Standard/Sample Dilution Buffer*. Perform 2-fold serial dilutions of the top standards to make the standard curve within the range of this assay (15.625 pg/ml ~ 1000 pg/ml) as below. *Standard/Sample Dilution Buffer* serves as the zero standard (0 pg/ml).

Standard	Add	Into
1000 pg/ml	250.0 μ l of the std.(4 ng/ml)	750.0 μ l of the <i>Standard/Sample Dilution Buffer</i>
500 pg/ml	500 μ l of the std.(1000 pg/ml)	500.0 μ l of the <i>Standard/Sample Dilution Buffer</i>
250 pg/ml	500 μ l of the std.(500 pg/ml)	500.0 μ l of the <i>Standard/Sample Dilution Buffer</i>
125 pg/ml	500 μ l of the std.(250 pg/ml)	500.0 μ l of the <i>Standard/Sample Dilution Buffer</i>
62.5 pg/ml	500 μ l of the std.(125 pg/ml)	500.0 μ l of the <i>Standard/Sample Dilution Buffer</i>
31.25 pg/ml	500 μ l of the std(62.5 pg/ml)	500.0 μ l of the <i>Standard/Sample Dilution Buffer</i>
15.625 pg/ml	500 μ l of the std.(31.25 pg/ml)	500.0 μ l of the <i>Standard/Sample Dilution Buffer</i>
0 pg/ml	1.0 ml of the <i>Standard/Sample Dilution Buffer</i>	

2) Secondary Antibody

100X secondary antibody solution can be made by adding 150 μ l *Secondary antibody/Streptavidin HRP dilution buffer* in the vial.

1. Equilibrate to room temperature, mix gently.

2. Mix 20 μ l *Secondary Antibody concentrated solution* (100X) + 1.98 ml *Secondary antibody/Streptavidin HRP dilution buffer*. (Sufficient for one 16-well strip, prepare more if necessary)

Label as “Working Secondary antibody Solution”.

3. Return the unused *Secondary Antibody concentrated solution* to the refrigerator.

3) Streptavidin HRP(X100)

1. Equilibrate to room temperature, mix gently.
2. Mix 20 μ l *Streptavidin HRP concentrated solution* (100X) + 1.98 ml *Secondary antibody/Streptavidin HRP dilution buffer*. (Sufficient for one 16-well strip, prepare more if needed)

Label as “Working Streptavidin HRP Solution”.

3. Return the unused *Streptavidin HRP concentrated solution* to the refrigerator.

4) Washing buffer

1. Equilibrate to room temperature, mix to re-dissolve any precipitated salt.
2. Mix 0.5 volume *Wash buffer concentrate solution* (20X) + 9.5 volumes of deionized water. Label as “Working Washing Solution”.
3. Store both the concentrated and the Working Washing Solution in the refrigerator.

* Directions for washing

1. Fill the wells with 300 μ l of “Working Washing Buffer”.
Let soak for 1 to 3 minutes and then all residual wash-liquid must be drained from the wells by aspiration (taking care not to scratch the inside of the well) or decantation, followed by forceful tapping of the plate on absorbent paper. Never insert absorbent paper directly into the wells.
If using an automated washer, the operating instructions for washing equipment should be carefully followed.
2. Incomplete washing will adversely affect the assay and renders false results.
3. It is recommended to use laboratory tape to hold plate strips to the plate frame while performing the plate washing to avoid strips coming free of the frame.

5) Sample preparation

Blood should be collected by venipuncture. For plasma samples, blood may be drawn into tubes containing sodium citrate or heparin, EDTA. The serum or plasma should be separated from the coagulated or packed cells by centrifugation. Samples may be shipped at room temperature and then stored refrigerated at 2-8°C if testing is to take place within one week after collection. If testing is to take place later than one week, samples should be stored at -20°C. Avoid repeated freeze/thawing.

9. Assay Procedure

- Allow all reagents to reach room temperature before use. Gently mix all liquid reagents prior to use.
 - All standards, controls and samples should be run in duplicate for confirmation of reproducibility.
 - A standard curve must be run with each assay.
 - If particulate matter is present in the analyte, centrifuge or filter prior to analysis.
 - Maintain a consistent order of components and reagents addition from well to well. This ensures equal incubation times for all wells.
- 1) Determine the number of 16-well strips needed for assay. Insert these in the flame(s) for current use (Re-bag extra strips and frame. Refrigerate for further use).
 - 2) For the standard curve, add 100 μ l of the standard to the appropriate microtiter wells. Add 100 μ l of the *Standard/Sample/secondary antibody Dilution Buffer* to zero wells.
 - 3) Serum and plasma require **at least 5 fold dilution** in the *Standard/Sample Dilution Buffer*. And add 100 μ l of samples to each well.
 - 4) Cover the plate with the plate cover and incubate for 2 hours at 37°C.
 - 5) Thoroughly aspirate or decant the solution from the wells. Wash the wells 3 times (See “Directions for washing”).
 - 6) Pipette 100 μ l of “Working Secondary Antibody Solution” into each well.
 - 7) Cover the plate with the plate cover and incubate for 1 hour at 37°C.
 - 8) Thoroughly aspirate or decant the solution from the wells. Wash the wells 3 times (See “Directions for washing”).
 - 9) Add 100 μ l “Working Streptavidin HRP Solution” to each well.
 - 10) Cover the plate with the plate cover and incubate for 30 minutes at 37°C.
 - 11) Thoroughly aspirate or decant the solution from the wells. Wash the wells 3 times (See “Directions for washing”).
 - 12) Add 100 μ l of *Substrate* to each well. The liquid in the wells should begin to turn blue.
 - 13) Incubate the plate at room temperature.
 - Do not cover the plate with aluminum foil, or color may develop. The incubation time for chromogen substrate is often determined by the microtiter plate reader used. O.D. values should be monitored and the substrate reaction stopped before O.D. of the positive wells exceeds the limits of the instrument. O.D. values at 450nm can only be read after the Stop Solution has been added to each well.
 - Because the *Substrate* is light sensitive, avoid the remained *Substrate* solution prolonged exposure to light.

- Typically, reaction is stopped 5~10 minutes after treatment of Substrate, but this time can be adjusted as the user desires.
- 14) Add 100 μ l of *Stop Solution* to each well. The solution in the wells should change from blue to yellow.
 - 15) Read the absorbance of each well at 450nm. Read the plate within 20 minutes of adding the *Stop Solution*.
 - 16) Plot on graph paper the absorbance of the standard against the standard concentration (Optimally, the background absorbance can be subtracted from all data points, including standards, unknowns and controls, prior to plotting.). Draw a smooth curve through these points to construct the standard curve.
 - 17) Read the Human IFN γ concentrations for the unknown samples and controls from the standard curve plotted in step 18. Multiply value(s) obtained for the unknown sample by the dilution factor (Samples producing signals greater than that of the highest standard should be further diluted in the *Standard/Sample Dilution Buffer*).

10. Characteristics

1) Typical result


The standard curve below is for illustration only and **should not be used** to calculate results in your assay.

A standard curve must be run with each assay.

Standard Human IFN γ (pg/ml)	Optical Density (at 450nm)
0	0.108
15.6	0.201
31.2	0.274
62.5	0.409
125	0.647
250	1.084
500	1.676
1000	2.326

< Limitations >

- Do not extrapolate the standard curve beyond the 1000 pg/ml standard point.
- Other buffers and matrices have not been investigated.
- The rate of degradation of native Human IFN γ in various matrices has not been investigated.



(TMB reaction incubate at room temperature for 5 min)

2) Sensitivity

The minimal detectable dose of Human IFN γ was calculated to be 15.262 pg/ml, by subtracting three standard deviations from the mean of 12 zero standard replicates (ELISA buffer, S0) and intersecting this value with the standard curve obtained in the same calculation.

N	1	2	3	4	5	6	7	8	9	10	11	12
ZERO	0.103	0.108	0.109	0.107	0.111	0.108	0.107	0.112	0.109	0.106	0.112	0.108

Average	SD	LLD	LLD mean(pg/ml)
0.108	0.003	0.117	15.262

3) Specificity

Detects human IFN γ in direct ELISAs and Western-blot. This antibody does not cross-react with recombinant mouse(rm) IFN γ , rrIFN γ , rpIFN γ , rfeIFN γ , or rcrIFN γ .

4) Precision

① Within-Run (Intra-Assay)

(n=12)

Mean (pg/ml)	SD (pg/ml)	CV (%)
132.790	9.960	7.501
258.814	21.553	8.327
492.663	33.147	6.728
881.280	59.113	6.708

② Between-Run (Inter-Assay)

(n=12)

Mean (pg/ml)	SD (pg/ml)	CV (%)
125.381	6.802	5.425
247.562	12.633	5.103
465.336	31.616	6.794
1047.336	123.902	11.830

5) Recovery

Recovery on addition is 116.041~127.100% (mean 119.458%)

Added Analyte (pg/ml)	Serum(1/5)+added analyte (450nm)	Serum(1/5)(450nm) +added analyte(450nm)	Recovery (%)
157.909	91.630	116.462	127.100
275.795	183.596	213.047	116.041
536.440	353.949	414.894	117.219
1029.842	784.101	921.101	117.472

11. Troubleshooting

Problem	Possible Cause	Solution
High signal and background in all wells	<ul style="list-style-type: none"> • Insufficient washing 	<ul style="list-style-type: none"> • Increase number of washes • Increase time of soaking between in wash
	<ul style="list-style-type: none"> • Too much Streptavidin-HRP 	<ul style="list-style-type: none"> • Check dilution, titration
	<ul style="list-style-type: none"> • Incubation time too long 	<ul style="list-style-type: none"> • Reduce incubation time
	<ul style="list-style-type: none"> • Development time too long 	<ul style="list-style-type: none"> • Decrease the incubation time before the stop solution is added
No signal	<ul style="list-style-type: none"> • Reagent added in incorrect order, or incorrectly prepared 	<ul style="list-style-type: none"> • Review protocol
	<ul style="list-style-type: none"> • Standard has gone bad (If there is a signal in the sample wells) 	<ul style="list-style-type: none"> • Check the condition of stored standard
	<ul style="list-style-type: none"> • Assay was conducted from an incorrect starting point 	<ul style="list-style-type: none"> • Reagents allows to come to 20~30°C before performing assay
Too much signal – whole plate turned uniformly blue	<ul style="list-style-type: none"> • Insufficient washing – unbound SAV-HRP remaining 	<ul style="list-style-type: none"> • Increase number of washes carefully
	<ul style="list-style-type: none"> • Too much Streptavidin -HRP 	<ul style="list-style-type: none"> • Check dilution
	<ul style="list-style-type: none"> • Plate sealer or reservoir reused, resulting in presence of residual Streptavidin -HRP 	<ul style="list-style-type: none"> • Use fresh plate sealer and reagent reservoir for each step
Standard curve achieved but poor discrimination between point	<ul style="list-style-type: none"> • Plate not developed long enough 	<ul style="list-style-type: none"> • Increase substrate solution incubation time
	<ul style="list-style-type: none"> • Improper calculation of standard curve dilution 	<ul style="list-style-type: none"> • Check dilution, make new standard curve
No signal when a signal is expected, but standard curve looks fine	<ul style="list-style-type: none"> • Sample matrix is masking detection 	<ul style="list-style-type: none"> • More diluted sample recommended
Samples are reading too high, but standard curve is fine	<ul style="list-style-type: none"> • Samples contain protein levels above assay range 	<ul style="list-style-type: none"> • Dilute samples and run again
Edge effect	<ul style="list-style-type: none"> • Uneven temperature around work surface 	<ul style="list-style-type: none"> • Avoid incubating plate in areas where environmental conditions vary • Use plate sealer

12. Reference

- 1) Thiel DJ, le Du MH, Walter RL, D'Arcy A, Chène C, Fountoulakis M, Garotta G, Winkler FK, Ealick SE (September 2000). "Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex". *Structure* **8** (9): 927–36.
- 2) Gray PW, Goeddel DV (August 1982). "Structure of the human immune interferon gene". *Nature* **298** (5877): 859–63.
- 3) Milstone, LM; Waksman BH (1970). "Release of virus inhibitor from tuberculin-sensitized peritoneal cells stimulated by antigen". *J Immunol* **105**: 1068–1071.
- 4) Naylor SL, Sakaguchi AY, Shows TB, Law ML, Goeddel DV, Gray PW (March 1983). "Human immune interferon gene is located on chromosome 12". *J. Exp. Med.* **157** (3): 1020–7.
- 5) Schoenborn JR, Wilson CB (2007). "Regulation of interferon-gamma during innate and adaptive immune responses". *Adv. Immunol.* **96**: 41–101.

◆ Ordering Information

For orders, please contact :

Immuno-Biological Laboratories, Inc. (IBL-America)

Address: 8201 Central Ave NE, Suite P, Minneapolis, MN 55432

Toll Free: (888) 523-1246

Fax: (763) 780-2988

E-mail: info@ibl-america.com

Website: www.ibl-america.com

For technical advice, please contact:

E-mail : info@ibl-america.com

Website : www.ibl-america.com